Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold

Citi analyst Hidemaru Yamaguchi has maintained their neutral stance on ALPMF stock, giving a Hold rating today.

Hidemaru Yamaguchi has given his Hold rating due to a combination of factors that balance near-term strength against lingering strategic uncertainties. Q3 revenue advanced 10% year over year and core operating profit jumped 39% to ¥159.4bn, topping the analyst’s ¥128.0bn estimate and consensus, thanks to standout U.S. demand for Xtandi and Mirabegron coupled with disciplined cost control and favorable currency effects. Management lifted full-year core operating profit guidance to ¥520bn, ¥30bn above the prior target and ahead of both the analyst’s model and the street, reinforcing the narrative of operational momentum.
Even so, the medium-term picture remains cloudy because investors remain fixated on the trajectory after Xtandi’s patent expiration, making upcoming R&D and strategy briefings in March and May pivotal for visibility. This mix of solid execution today but unresolved post-cliff earnings power leads Yamaguchi to view the stock as fairly valued despite an expected 11.2% share price return, supporting a Hold stance pending clearer long-term catalysts.

According to TipRanks, Yamaguchi is an analyst with an average return of -0.6% and a 47.37% success rate. Yamaguchi covers the Healthcare sector, focusing on stocks such as Sosei Group, Daiichi Sankyo Company, and M3.

In another report released today, Bernstein also maintained a Hold rating on the stock with a Yen2,000.00 price target.